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Strengths and limitations of this study
 ► A key strength of the study is the use of mixed meth-
ods to evaluate an innovative series of workshop for 
citizen health advocates, about conflicts of interest 
in healthcare.
 ► The qualitative analysis of participant discussion 
offers a rare insight into citizen health advocate per-
spectives of two major contemporary issues, trans-
parency and the merits of financial relationships 
with industry.
 ► The workshops were planned and delivered with in-
put and participation from leading Australian citizen 
health advocacy groups.
 ► A key limitation is that the workshop participants 
were not representative, but rather recruited through 
advertising by advocacy groups.
AbStrACt
Objectives To evaluate workshops delivered to citizen 
health advocates about financial conflicts of interest in 
healthcare, transparency databases which disclose industry 
payments in the USA and Australia and the pros and cons of 
advocacy groups accepting industry sponsorship.
Design Thematic analysis of workshop participant 
recorded discussions, and pre, post and 3- month follow- up 
questionnaires on confidence and knowledge about financial 
conflicts of interest, transparency databases and the merits 
of advocacy organisations accepting industry sponsorship.
Participants and setting 48 citizen health advocates 
participated in a half- day workshop, held in four Australian 
cities, which ended with a 1- hour recorded discussion. 
Participants were recruited with assistance from leading 
state- based health advocacy organisations.
results The thematic analysis of the recorded 
discussions revealed two major themes, (i) transparency 
and (ii) relationships with industry; and three minor 
themes: a lack of awareness about conflicts of interest 
and transparency, issues relating to trust and next steps 
in terms of potential reforms. In relation to transparency, 
participants felt strong support for transparency, strongly 
favouring the mandatory, extensive and accessible US 
Open Payments over the self- regulatory Australian model. 
Participants also noted that transparency had limitations, 
including the utility of disclosed information. In relation 
to industry sponsorship of advocacy groups, some 
participants expressed an openness to and support for 
accepting sponsorship, while many expressed a caution 
around potential downsides. Questionnaire results showed 
increases in both confidence and knowledge after the 
workshop, though only 23 of 48 participants returned the 
3- month follow- up questionnaire.
Conclusions Following a half- day workshop, citizen 
health advocates recruited by leading health advocacy 
organisations expressed strong support for tough 
transparency rules, and mixed feelings about advocacy 
groups accepting sponsorship from industry. Study 
limitations include a non- representative sample and a 
large drop- out at the 3- month post- workshop follow- up.
IntrODuCtIOn
Extensive financial conflicts of interest are 
recognised as a major challenge within 
healthcare, potentially jeopardising the 
integrity of medical research, education and 
practice.1 2 Industry- sponsored trials are more 
likely to find favourable results for spon-
sors’ products.2 Doctors attending industry- 
funded educational events are more likely to 
prescribe sponsors’ products.3 Specialists with 
financial ties to industry tend to make favour-
able statements about sponsors’ products.4 
And guideline panels which set and expand 
disease definitions often comprise a majority 
of members with financial ties to industry.5 
At the same time there is growing evidence 
that many consumer or citizen health advo-
cacy groups are reliant on industry funding.6 
These groups play increasingly important 
roles, including advocating for patients, co- de-
signing research and contributing to guide-
line development, and there are concerns 
that financial conflicts may be distorting the 
patient voice in healthcare.7 8
As a result of growing concerns about 
the distorting impacts of endemic financial 
ties to industry, there have been moves in 
many countries towards more transparency 
in healthcare. As a result, new databases 
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box 1 Content of workshops for citizen health advocates
The first section introduced evidence about industry sponsorship of re-
search and medical education. The first small group session used the 
Australian transparency database22 which included company provided 
PDFs to find examples of industry sponsored educational events.*
The second section introduced evidence about industry sponsorship of 
individual scientists, or ‘key opinion leaders’, and the small- group exer-
cise involved live searching of the US Open Payments database to find 
disclosures of individual doctors.
The third section focussed on industry funding of patient/advocacy 
groups, and the small- group exercise involved live searching of the 
Australian transparency database to find and discuss examples of ad-
vocacy groups receiving funding.
The fourth section involved a recorded 1- hour discussion, to explore 
participants views and feelings about the workshop content. While 
a structured guide was available, the aim was for an open and free- 
flowing discussion.
*One of several elements of the Australian transparency system moved from 
PDFs to a searchable database in August 2019.
are becoming available with details about ties between 
industry, individuals and organisations. In the USA, 
a series of high- profile congressional investigations 
into financial conflicts of interest in healthcare ulti-
mately led to the passing of a bipartisan law, The Physi-
cian Payments Sunshine Act, commonly known as the 
Sunshine Act. As a result of this law, since 2013 pharma-
ceutical companies have had to disclose all payments to 
doctors in a highly accessible government- run database, 
called Open Payments. (https://www. cms. gov/ open-
payments/). In 2018, new legislation was introduced in 
the USA proposing to extend the existing law, so that 
all industry payments to advocacy groups would have 
to be disclosed in the database.9 Australia, like many 
countries, does not have legally binding mandatory 
disclosure, although its industry- controlled system does 
include disclosure of payments to consumer groups.10
Alongside moves to transparency, there are growing 
calls for more independence between industry and 
other sectors within healthcare, including in research, 
education and practice,1 particularly in light of growing 
evidence of the problems of overdiagnosis and overuse 
within healthcare.11 For example, the British Medical 
Journal (BMJ) has undertaken a number of indepen-
dence initiatives, such as excluding authors with finan-
cial ties from publishing educational content or clinical 
guidelines, and ending advertising revenues from breast 
milk substitute manufacturers.11 Others have advocated 
that the leadership of influential professional medical 
associations, responsible for much research and educa-
tion, should be entirely free of financial ties to industry.12
There have been limited attempts to share the evidence 
about financial conflicts of interest in healthcare in non- 
medical settings. Odierna and colleagues conducted and 
evaluated workshops for non- medical participants in the 
USA, which included citizen/consumers, and covered 
elements related to financial conflicts of interest.13 14 In 
Australia, we have previously conducted two workshops 
with journalists, introducing the evidence about financial 
conflicts of interest and interacting with transparency 
databases,15 16 though without any evaluation. In light 
of the importance of public understanding of finan-
cial conflicts of interest,1 increasing scrutiny of industry 
funding of advocacy groups8 and calls for greater inde-
pendence,11 we aimed to evaluate workshops which 
introduced citizens to financial conflicts of interest and 
transparency databases, and engendered discussion 
about industry sponsorship of advocacy organisations. 
While the terms ‘consumer’, ‘patient’, ‘citizen’ and ‘advo-
cate’ are all used, for the purposes of consistency, we have 
used ‘citizen’ in this manuscript.
MethOD
Summary
We worked with leading state- based Australian citizen (or 
consumer) peak health organisations to recruit people 
involved in advocacy to attend a half- day workshop, in 
each of four state capital cities in Australia. We used both 
quantitative and qualitative methods to evaluate work-
shops which: (i) introduced participants to the evidence 
about the extent and impacts of financial conflicts of 
interest in healthcare; (ii) introduced workshop partici-
pants to the transparency databases, from the USA and 
Australia, which feature details including the financial ties 
to industry, of individual health professionals, researchers 
and consumer groups; (iii) facilitated discussion among 
participants about financial conflicts of interest including 
their relevance to citizen health advocacy organisations. 
For the small quantitative component, we evaluated the 
workshop using very brief questionnaires to measure 
effects on knowledge and confidence about financial 
conflicts of interest and transparency databases, pre, post 
and after 3 months. The questionnaires were based on 
similar tools used previously by Odierna and colleagues.14 
For the qualitative evaluation, we evaluated transcripts of 
1- hour facilitated discussions with all participants which 
were recorded at the end of each workshop, drawing on 
framework analysis methods previously used in a research 
project with community focus groups,17 and based on the 
methods outlined by Ritchie and colleagues.18
Workshop content
The content of the 4- hour workshop was based on similar 
workshops on conflicts of interests, delivered to Australian 
journalists, with support from Cochrane Australia,15 16 but 
modified for citizen participants. The workshop materials 
consisted of a series of short didactic PowerPoint presen-
tations, (online supplementary file 1) followed by a series 
of small- group activities and discussions. The structure of 
the workshop opened with an introduction to definitions 
of conflicts of interest in healthcare, followed by four 
main sections (see box 1.) Workshop content was devel-
oped and delivered by two academic researchers who 
conduct research on the impacts of conflicts of interest 
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on research and practice, and have previously conducted 
qualitative research including focus groups, authors RM 
(male) and LB (female), who disclosed their conflicts of 
interests, and interests in the topic, at the beginning of 
the workshop.
Workshop recruitment
Participants were recruited with assistance from each of 
the state- based peak or umbrella groups which hosted a 
workshop. Each organisation sent a short description of 
the workshop to their networks. Participation was open 
to both organisation staff, and citizens connected to the 
organisation. Interested participants were sent an Explan-
atory Statement (online supplementary file 2) about 
the workshops and evaluation research, and all signed 
consent forms before participating. We aimed to recruit 
between 50 and 100 participants, at up to five workshops. 
Participants were not reimbursed, but received travel 
assistance when requested, and refreshments and a light 
lunch, provided by the citizen organisations and in one 
instance, the University of Sydney. LB and RM paid for 
their own travel expenses.
Workshop evaluation and analysis
The theoretical framework underpinning the qualitative 
aspects of the study, was drawn from the phenomenology 
approach, which seeks to comprehend the ‘constructs, 
concepts or ideas people use in everyday life to make 
sense of their world’.18 The methods used to evaluate the 
themes of the 1- hour recorded discussions with partici-
pants were a simplified version of ‘framework analysis’ 
method as described by Ritchie and colleagues18 and used 
previously by Moynihan and colleagues.17 Two authors, 
RM and AF independently assessed the transcripts of 
all four workshops and developed a draft framework of 
themes and subthemes, in Excel. These were merged 
and shared with co- authors LP and LB, who each read 
one transcript, and offered feedback on the themes and 
subthemes. RM and AF then each coded all four tran-
scripts to the framework, and preliminary findings were 
shared with co- authors for comment, and then refined.
The quantitative evaluation of confidence and knowl-
edge was a simple, very brief questionnaire, (online 
supplementary file 3) based on the short questionnaire 
used by Odierna and colleagues in evaluating a similar 
workshop on critical appraisal, which was based on vali-
dated and previously used instruments,14 and modified 
during pilot testing. Six questions about confidence 
covered: confidence in explaining a financial conflict of 
interest, and a systematic review of studies; confidence in 
ability to use the Australian transparency database, and 
the US database; confidence in ability to discuss evidence 
about the impacts of industry sponsorship of research, 
and the pros and cons of accepting industry sponsorship 
from a pharmaceutical company. Three questions about 
knowledge covered the most reliable source of evidence, 
the source of information on industry payments in 
Australia and the minimum threshold of payment for 
disclosure in the USA.
The questionnaire was given to participants prior 
to the start of the workshop, at the conclusion and was 
emailed 3 months later, with one email reminder. The 
pre- questionnaire also asked basic demographic ques-
tions including: how participants would describe them-
selves, gender, education and age. For the quantitative 
analysis, for each confidence question, we compared the 
proportion of respondents who indicated 4 or 5 on a 1 to 
5 scale of confidence, pre workshop, post workshop and 
at 3 months, using McNemar’s test. For each knowledge 
question in our questionnaire, we compared the propor-
tion of correct answers, pre and post workshop, and at 
3 months, using McNemar’s test.
research team
In line with the Consolidated criteria for Reporting 
Qualitative research checklist for the reporting qualita-
tive research,19 we report that we have expertise across 
overdiagnosis, pharmacy, research integrity, public health 
ethics, medicine and evidence- informed practice. RM 
is a postdoctoral researcher with a long- term interest 
in conflicts of interest, greater independence between 
industry and other sectors within healthcare and overdiag-
nosis. AF is a postdoctoral researcher whose work focusses 
on pharmaceutical policy and commercial influences on 
health. LP is a bioethicist, medical clinician and a post-
doctoral researcher whose work focusses on pharma-
ceutical policy and commercial influences in health. LB 
uses mixed methods in her research on bias, conflicts of 
interest, research integrity and research implementation 
in biomedicine and public health, which spans decades.
All workshop participants read the Explanatory State-
ment and gave written informed consent.
Patient and public involvement
Staff from leading state- based citizen/consumer health 
organisations gave feedback on the plans to deliver and 
evaluate the workshops, helped recruit participants, 
hosted three of the workshops and co- hosted the fourth.
reSultS
Four organisations agreed to host a workshop in a state 
capital city: Health Consumers Queensland in Brisbane; 
Health Consumers New South Wales in Sydney; Health 
Issues Centre in Melbourne and the Health Consumers 
Alliance of South Australia, Inc, in Adelaide. A total of 48 
participants took part in the workshops, with an average 
age of 60, and basic demographic information is available 
in table 1.
Qualitative findings
Summary
The structured guide for the recorded 1- hour discussion 
proved largely redundant, as participants enthusiastically 
engaged in discussion about the material covered in the 
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Table 1 Workshop participant characteristics. (n=48)
How would you describe yourself*
  Consumer/carer 26
  Advocate 29
  Staff member of consumer group 8
Gender
  Female 41
  Male 7
Education
  University 45
  Other 3
*Not- mutually exclusive categories.
workshop. Our framework analysis of the transcripts of 
the four recorded discussions revealed two major themes, 
and three minor themes. The first major theme was trans-
parency, with a range of views and feelings, but overall 
very strong support for public disclosure of financial 
relationships between industry and other players within 
healthcare, including professionals and advocacy groups. 
The second major theme was about financial relation-
ships between industry and advocacy organisations, with 
discussions featuring an openness to and sometimes 
support for relationships, as well as common and strong 
concerns about potential downsides. Minor themes 
included: a general lack of awareness about the evidence 
around conflicts of interest and transparency databases; 
trust, which emerged briefly in discussions in different 
ways and next steps, in terms of possible reforms.
transparency
The dominant theme of the recorded discussions was 
around the importance of transparency, with almost 
universal support for the idea of improving transparency 
systems to maximise disclosure. After using both the USA 
and Australian databases in exercises during the work-
shop, participants were able to compare both systems. Two 
important subthemes were the weakness of the Australian 
system as compared with the strengths of the US system, 
and the limits to the impacts of transparency alone.
Strength of US transparency database and weakness of Australian 
database
The US Open Payments transparency database was 
discussed very positively by many of the participants, 
described variously as: ‘absolutely fantastic’, ‘far more 
extensive’, ‘much more accessible’, ‘far superior’, ‘much 
more transparent’. The Australian database, managed 
by the pharmaceutical industry under a self- regulated 
system, rather than run by the national government, was 
criticised as much harder to search, much less extensive 
due to exclusion of hospitality payments and not manda-
tory. At the time of the workshops Australian data was only 
available in individual PDFs supplied from each company.
Yeah, it's like we put something there, there you go, 
we're being transparent, but we don't want you to ac-
tually know how to actually find anything and if you 
do, you're going to spend the next 3 weeks stuck in 
this rabbit hole…
The limitations of transparency
While transparency was strongly supported, it was not 
regarded by all participants as a panacea for addressing 
the problem of financial conflicts of interest. It was viewed 
by some as a ‘really important first step’ towards more 
independence, but for others transparency had limited 
utility.
I'm not sure whether increased transparency will 
change the culture; and I think it is a cultural prob-
lem that exists between doctors and the pharmaceu-
tical and the medical technology companies and it is 
dangerous, very.
relationships with industry
The second key theme was discussion of potential posi-
tives and potential negatives of financial relationships 
between citizen/patient/consumer groups and industry 
sponsors. While there was some support for the idea from 
some participants, and an openness to it, there was much 
more discussion of potential downsides. Importantly, 
while pharmaceuticals is the most identifiable industry in 
healthcare, there was a common view that similar debates 
apply to other industries, including device- makers or 
private insurers.
Positive views of ties with industry
While several participants expressed an openness to the 
positive impacts of accepting industry sponsorship, one 
participant repeatedly offered very strong endorsement 
of the relationship. A key argument in favour of spon-
sorship from industry was that sometimes it is the only 
source of funding, that there is not enough non- industry 
funding, and funding is needed to enable citizen groups 
to undertake valuable advocacy and produce materials 
for patients:
…if the pharmaceutical companies weren't funding 
it…who would? You wouldn't get it from anybody else
The concern expressed was that valuable activities of 
advocacy groups may stop if industry sponsorship was lost:
…in consumer advocacy groups, the main one that 
I'm involved with, we don't receive any funding at all, 
but I know of other groups that have and it's been 
used in a very appropriate way and it's raised aware-
ness, it's created fundraising, awareness with govern-
ment and ultimately influencing more funding for 
particular research…
Other support for industry sponsorship came from 
participants involved with groups who accepted it, who 
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argued there was benefit, and there was no evidence of 
unhealthy influence:
As I mentioned before, I'm part of an organisation 
that relies quite heavily on that and so I see the bene-
fits all the time. I, to this point, haven't seen any neg-
atives from it, so I just see all the work that it's doing 
and what it can potentially be doing
Another participant reflected that sponsorship was 
more acceptable, given that advocacy groups did not 
prescribe:
…in terms of then their real influence, they're not 
actually the prescribers of the medication.
Negative views of industry sponsorship
The most common concern from participants was that 
industry sponsorship would bring potentially unhealthy 
influences or biasses to their activities:
…you're going to think more favourably of that com-
pany. Anybody that's going to sponsor you, you're go-
ing to be more favourable towards…
One specific potential impact of pharmaceutical 
company sponsorship on advocacy groups which came up 
in discussion was the possibility the group may be used as 
part of the marketing of a product, including lobbying for 
listing for reimbursement on Australia’s national formu-
lary, the Pharmaceutical Benefits Scheme, or PBS.
…it is my understanding that there is encouragement 
by pharmaceutical companies for patient - perspec-
tive patients, shall we say, to write to the PBS prior to 
listing in an effort to get products listed.
The threat that sponsorship poses to independence was 
another issue which emerged in discussion:
…we've been really clear that we want our policies to 
be fit for the purpose of our organisation and if we 
are saying we're 100 per cent independent volunteer 
organisation, then we're not going to accept money 
from pharmaceutical companies, because that would 
bias our independence
Responding to the view that industry sponsorship was 
often all that was available to fund advocacy activity, one 
participant stated:
my final comment would be something is not always 
better than nothing.
lack of awareness of evidence and databases
There was a general view that participants had not heard 
much about the existing research on conflicts of interest 
in healthcare, or the publicly accessible transparency 
databases:
We are all involved and reasonably knowledgeable 
and yet I think many of us, I have, been taken by sur-
prise at what's happening
trust
The issue of trust came up a number of times in different 
ways during discussion. Some participants recognised 
that their groups independence was seen by patients as a 
reason for their trustworthiness :
People phone our information phone line and say, 
what doctor should I see, should I take this drug, 
they're asking—and we say, we can't give medical ad-
vice, but they ask us because they trust us.
Other participants noted that ties with industry might 
be seen by some to threaten both their independence 
and reputation:
The question really needs to be raised to clinicians 
and to patient support groups about how their repu-
tation comes across
One participant thought that wider public debate about 
conflicts of interest might undermine public trust:
I actually worry a little bit about this topic getting out 
there, because it does destroy trust
And others thought transparency could help to build 
trust:
I think the whole question is really important and 
this thing about trust and transparency is really, really 
important.
next steps
In discussion about possible future reforms, as mentioned 
above there was strong support for greatly enhanced 
transparency rules, in line with the mandatory govern-
ment- run US system, but extended to cover other indus-
tries active in health, and to cover all payments to all 
organisations, including advocacy groups. In relation to 
industry sponsorship of advocacy groups, participants 
felt a need for more scrutiny of what sponsors wanted 
in return, new policies to help guide relationships and 
wider awareness- raising and debate about pros and cons 
of sponsorship, within a context of respect:
…getting back to the patient groups, I really, really 
feel that however (the topic of financial relation-
ships with industry) is targeted has to be done with 
a great deal of sensitivity if you're opposing that, be-
cause we're talking about people and their narrative 
and there is so much power in the narrative and so 
that has to be honoured. So if you're actually going 
to come up in any way at all, it's not from a point of 
discrediting, it's a means of opening up further and 
it can never be, well you're wrong and we're right be-
cause it can never be that.
Quantitative findings
Analysis of the brief questionnaire found small improve-
ments in confidence and knowledge. Forty- eight partic-
ipants completed the pre and post questionnaires, with 
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minimal missing data for each question. Only 23 partici-
pants completed the questionnaire at 3 months follow- up. 
For all six questions about confidence in ability to under-
stand and discuss concepts about conflicts of interest and 
ability to use databases, comparisons showed increases 
in confidence between pre and post workshop, and pre 
workshop and 3- month follow- up (online supplementary 
file 4).
As for knowledge, there were small but statistically 
significant increases in the number of correct answers 
to two of the three questions, between pre and post, and 
between pre and 3- month follow- up, using McNemar’s 
test, with the important caveat that just under 50% of 
participants did not submit a questionnaire at 3 months 
(online supplementary file 4). Reasons for not submitting 
were not solicited from participants. There were increases 
for question 8 (about which form of evidence is most reli-
able), and question 10 (about the threshold for disclo-
sure in the USA). There was no statistically significant 
change in the numbr of correct answers to question 9, 
about the current best source of transparency informa-
tion in Australia.
DISCuSSIOn
Our results suggest an appetite among citizen health advo-
cates and their organisations to understand and engage 
more with evidence and data about financial conflicts 
of interest in healthcare, and that accessible workshops 
on the topic can be successfully designed and delivered. 
Analysis of brief questionnaires given pre and post work-
shop and at 3 months follow- up suggest the potential for 
workshops to modestly improve confidence and knowl-
edge around the major challenge of addressing financial 
conflicts of interest within healthcare. Qualitative anal-
ysis of recorded discussions indicates strong support for 
enhanced transparency rules, mixed feelings about the 
merits of advocacy groups accepting industry sponsorship 
and a need for more scrutiny and debate around these 
relationships.
Our study had important limitations. The primary 
limitation is that the sample of 48 participants was not 
designed to be representative: they were recruited via 
information from leading organisations, and clearly have 
an interest in the topic. Second, just over half of all partic-
ipants did not return a questionnaire at 3 months, despite 
one email and a friendly reminder. And third the number 
of participants is relatively small. The chief strength of the 
study was its novel ability to facilitate a more informed 
discussion among active citizen health advocates about 
the evidence on financial conflicts of interest. The study 
also offered an extremely rare opportunity to hear the 
voices of citizens reflecting on highly salient contempo-
rary debates within healthcare around both transparency, 
and independence from industry. A final strength lies in 
demonstrating a capacity to design and deliver complex 
materials on these topics in non- medical settings.
To our knowledge this was one of the first projects to 
design and evaluate workshops for citizen advocates about 
the issue of financial conflicts of interest. Odierna and 
colleagues have previously evaluated workshops for non- 
medical participants in the USA, which included some 
materials related to financial conflicts of interest.13 14 
An analysis of the workshops published in 2012, which 
involved 102 consumers and 33 journalists, found 
improvements in confidence and knowledge in relation 
to critical appraisal of health evidence.14 A later analysis 
demonstrated how the workshops on critical appraisal 
had successfully included material on the ‘cycle of bias’ 
in healthcare and detecting financial and other conflicts 
within medical research.13
Evidence and concerns about financial conflicts of 
interest are intersecting with evidence and concern about 
too much medicine, including the challenge of overdiag-
nosis, resulting in stronger calls for more independence 
from commercial influence in healthcare.11 20 21 Notwith-
standing important limitations, our study demonstrates 
it is both feasible and desirable to engage citizen advo-
cacy organisations and their wider networks in a broader 
evidence- informed conversation about these challenges. 
Our findings suggest such workshops could feasibly be 
made available more broadly to both the general popula-
tion, as well as within healthcare settings. On the question 
of transparency, participants expressed almost universal 
support for tough transparency rules, along the lines of 
the mandatory US system, strengthening the case for 
reform.20 One very practical outcome has been a new 
national meeting on these issues taking place in Australia 
in 2020, where citizen advocates will discuss the merits of 
industry funding and the challenges of finding funding 
from other sources.
Our results suggest three possible areas for future 
research. First, further qualitative research with citizen 
health advocates in different nations, about both trans-
parency and the merits of independence, may be fruitful. 
Second, studies comparing processes and experiences 
with different transparency systems may be warranted. 
Third, more quantitative work on the ways in which 
industry sponsorship impacts in both hidden and tangible 
ways on advocacy groups is urgently needed. As emerged 
in the workshop discussions, like health professionals, and 
medical researchers, advocacy groups believe that they 
currently command a certain trust in the public imagina-
tion. As more groups become reliant on industry funding, 
and evidence about conflicts of interest becomes better 
known, the impacts on that trust are unclear.
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